Puma Biotechnology

$11.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.42 (+3.86%) Today
$0.00 (0.00%) As of 9:33 PM UTC after-hours

Why Robinhood?

You can buy or sell PBYI and other stocks, options, and ETFs commission-free!

About PBYI

Puma Biotechnology Inc Common Stock, also called Puma Biotechnology, is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA. The listed name for PBYI is Puma Biotechnology Inc Common Stock.

CEO
Alan H. Auerbach
Employees
269
Headquarters
Los Angeles, California
Founded
2010
Market Cap
463.95M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
470.20K
High Today
$11.34
Low Today
$10.82
Open Price
$10.82
Volume
212.27K
52 Week High
$14.14
52 Week Low
$5.50

PBYI News

BenzingaFeb 20

Tigerlily Foundation Launches a New Web Series, BREATHE Tv on Facebook Live

Stone Ridge, VA, February 20, 2021 --(PR.com)-- Tigerlily Foundation in partnership with Puma Biotechnology, Inc. is excited to announce the launch of BREATHE T

PBYI Earnings

-$1.00
-$0.55
-$0.10
$0.35
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.29 per share
Actual
Available Feb 25, After Hours
Preview Earnings Call

You May Also Like

HLI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure